Meta-analysis of 67 observational studies (17,441 pregnancies) with IBD advanced therapies: pooled early pregnancy loss 8.2%, preterm birth 8.9%, stillbirth 0.3%, malformations 2.9%. JAK inhibitors and ustekinumab were linked to more early loss, vedolizumab to more preterm birth.
Meta-analysisn = 17,441 pregnancies
Moraes et al. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis